- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
3 Reasons Insurance Premiums Won't 'Skyrocket' Next Year
Despite what some media reports have to say, health insurance premiums won't "skyrocket" next year, according to an article by ConsumerReports.
Despite what some media reports have to say, health insurance premiums won't "skyrocket" next year, according to an article by ConsumerReports.
Why? For one, "some states are using regulatory mojo to roll back outrageous requests," the article said.
"Some states have the authority to review rates, and do," Betsy Imholz, a health insurance expert for Consumer Reports, said. "In other states there have been negotiated reductions."
In Oregon, for instance, average 2015 premiums came in lower than 2014 rates after regulators got done with them, according to Oregon.gov. In Maryland, CareFirst, the state's dominant insurer, asked for a 23 to 30 percent increase, but was granted increases of 10 to 16 percent, The Washington Post reported. Rates are decreasing for other insurers, ConsumerReports said.
Read the full story: http://bit.ly/1CqJsEx
Source: FierceHealthPayer
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
